Interleukin 13 and its role in gut defence and inflammation

Peter Mannon, Walter Reinisch

Research output: Contribution to journalReview article

70 Scopus citations

Abstract

Interleukin 13 (IL-13) is a cytokine of increasing interest to gastroenterologists because of its developing role in ulcerative colitis, eosinophilic oesophagitis (EO) and fibrosis. Recent data show that IL-13 may play an important role in a novel innate immune response since it can be released by signals from an injured or inflamed epithelium, of particular relevance to the gut. Animal models of IL-13-driven inflammation (from asthma to colitis and EO) are being translated to human disease and providing insight into potential strategies for new therapies. In fact, multiple clinical trials using anti-IL-13 drugs are underway in asthma and are being extended to gastrointestinal diseases. This review presents the current knowledge on IL-13 production and function in the gut, including the cells and receptor signalling pathways involved in mediating IL-13 effects, the proposed mechanisms of IL-13 induced gut disease and the many drugs currently being tested that target IL-13 related pathways.

Original languageEnglish (US)
Pages (from-to)1765-1773
Number of pages9
JournalGut
Volume61
Issue number12
DOIs
StatePublished - Dec 2012

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Interleukin 13 and its role in gut defence and inflammation'. Together they form a unique fingerprint.

  • Cite this